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Summary: We address discrete-marks survival analysis, also known as categorical sieve analysis, for a setting of a
randomized placebo-controlled treatment intervention to prevent infection by a pathogen to which multiple exposures
are possible, with a finite number of types of “failure”. In particular, we address the case of interventions that are
partially efficacious due to a combination of failure-type-dependent efficacy and subject-dependent efficacy, for an
intervention that is “non-leaky” (where “leaky” interventions are those for which each exposure event has a chance of
resulting in a “failure” outcome, so multiple exposures to pathogens of a single type increase the chance of failure).
We introduce the notion of some-or-none interventions, which are completely effective only against some of the
failure types, and are completely ineffective against the others. Under conditions of no intervention-induced failures,
we introduce a framework and Bayesian and frequentist methods to detect and quantify the extent to which an
intervention’s partial efficacy is attributable to uneven efficacy across the failure types rather than to incomplete
“take” of the intervention. These new methods provide more power than existing methods to detect sieve effects when
the conditions hold. We demonstrate the new framework and methods with simulation results and new analyses of
genomic signatures of HIV-1 vaccine effects in the STEP and RV144 vaccine efficacy trials.
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1. Introduction
Despite advances in both treatment and prevention, the global HIV/AIDS epidemic continues
to levy a heavy toll on millions of HIV-infected individuals and those who love them. With a
global prevalence of over 33 million, and an estimated 14% prevalence among women and men
aged 15-49 in some subsaharan African states where non-vaccine interventions are difficult
to scale to a population level, there is great need for an effective public health vaccine (ICF
International, 2012).
There is no licensed vaccine to prevent infection by HIV. While some vaccines have
been relatively easy to develop, creating effective vaccines against HIV has proven more
challenging. In response to the slow pace of the traditional strategy for vaccine development,
organizations such as the Global HIV-1 Vaccine Enterprise are advocating for more iterative
strategies, in which even “failed” clinical trials nevertheless provide maximal insight into
mechanisms of whatever partial protection may have been conferred to some subset of vaccine
recipients (Berkley et al., 2010).
One critical question that arises in such an approach is, in the aftermath of a randomized
clinical trial to evaluate a new treatment intervention, to what extent should observed
differences in apparent efficacy across outcome types be attributed to actual imbalanced
efficacy across those types, as opposed to imbalanced uptake across subjects, or to just poor
efficacy overall? This is non-trivial because other factors may also lead to a difference in
observed failure rates across types, other than differential efficacy of the intervention to
prevent type-specific failures.
A sieve analysis investigates an interventions’s efficacy as a function of specific features
of the outcome (Edlefsen et al., 2013). A recent example comes from a sieve analysis of the
RV144 HIV-1 vaccine efficacy trial. The RV144 vaccine regimen was partially efficacious at
reducing HIV-1 acquisition risk among healthy low-risk Thai volunteers, with an estimated
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intervention efficacy (IE) of 31% versus placebo (Rerks-Ngarm et al., 2009). A subsequent
sieve analysis identified that this efficacy significantly differed against viruses of two types
that are differentiated by a viral genome feature at an immunologically relevant locus (Rol-
land and Edlefsen et al., 2012). This result concords with other evidence that the vaccine
induced antibodies that target a specific region (called V2) of the viral envelope (Haynes
et al., 2012), and together these results are influencing ongoing and planned HIV-1 vaccine
trials.
Sieve analysis can also provide valuable insight into an intervention’s effect in the context
of an intervention with no overall efficacy. An example comes from the STEP HIV-1 vaccine
efficacy trial, which was halted early for efficacy futility (Buchbinder et al., 2008). STEP
evaluated a vaccine candidate in high-risk study participants in the Americas. At its early
conclusion, the estimated hazard ratio of infection (vaccine vs placebo) was about 1.5. A
sieve identified vaccine-driven selective pressure at an immunologically-relevant HIV-1 locus,
indicating that although it did not reduce the overall acquisition rate, the vaccine did induce
an immune response that affected the distribution of observed viruses, possibly by altering
the dynamics of post-infection viral evolution (Rolland et al., 2011).
Sieve analysis is also known as “mark-specific efficacy analysis”, where the general term
“mark”refers to features of the failure (as opposed to covariates of the subject). Sieve analysis
methods have been developed for a variety of types of marks (e.g. Gilbert et al., 1998,
2008; Juraska and Gilbert, 2013). Common example features include pathogen serotypes,
and quantitative measures of pathogen susceptibility to neutralization. The framework that
we introduce in this article addresses finite-category nominal marks.
Peter Gilbert enumerated several conditions that are required to yield unbiased estimates
of mark-specific intervention efficacy for the case of a “leaky” intervention (Gilbert et al.,
1998; Gilbert, 2001). The notion of a “leaky” intervention was introduced by Struchiner et al.
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(1990) in contrast with an “all-or-none” intervention (Halloran et al., 1991) for a setting in
which failure types are not differentiated, and has been extensively developed for applications
in that setting (Halloran et al., 2010). In the former case, each of a subject’s potentially-
multiple exposures has some chance of being thwarted by the effect of the intervention; in
the latter case, each subject is either a responder (and therefore protected if exposed) or not.
In vaccine trials, responders are said to have “take” of the vaccine.
Peter Gilbert argued and showed through simulation studies that his conditions for un-
biased sieve analysis are violated whenever some subjects have no “take” (Gilbert, 2000).
We introduce a new variant on the “leaky” vs “all-or-none” dichotomy: the “sievey-not-leaky”
intervention, which exhibits sieve effects but not per-event stochastic leaks. We call such an
intervention “some-or-none”, as it completely protects subjects with “take” - but only against
failures with marks that fall in an “intervention-targeted” subset. We provide analogous
conditions for unbiased assessment of sieve effects in this non-leaky setting, and introduce
the “sievey-not-leaky” modeling framework for evaluating a some-or-none intervention under
the “no-harm” condition (that the intervention can prevent would-be-failures but cannot
induce new failures or increase susceptibility).
We also provide a new perspective on the “Model-Based Sieve” (MBS) method that was
employed in the RV144 sieve analysis (Rolland and Edlefsen et al., 2012), and show that it
can be understood either as an approximation to the some-or-none intervention model or as
a model of the effects of the intervention on post-infection variation.
The scope of the present work is limited to categorical representations of all outcomes. Fu-
ture work incorporating time-to-event data into the framework is likely to improve efficiency
of the methods. Note too that this representation necessitates excluding subjects lost-to-
followup before the end of the trial (assuming conditions of uninformative missingness), who
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may contribute information relevant to estimation of intervention efficacy but would not (in
this framework) contribute to the estimation of relative failure rates across failure types.
In the Results section we present new analyses of the genomic sequences of the HIV-1
viruses that infected participants of the RV144 and STEP trials, in which the mark types
are the amino acids (AAs) found in the genome of each virus at a particular locus of interest.
In that setting, one particular AA is unique because it was included in the vaccine (so we
expect that sieve effects will reflect greatest efficacy against this targeted category) but the
other AAs are unordered. We address the general problem of sieve analysis for unordered
categories, and are particularly motivated by settings in which some categories are targets
of the intervention and others are not.
The remainder of this article is organized as follows. First we describe the “sievey-not-
leaky” (SNL) modeling framework. Although we assume that the intervention does not
induce new failures, sieve effects may lead to type-specific increases in the observed failure
rates due to replacement of avoided failures by failures of other types. We discuss the
potentially confounding effects of such “replacement causes” on efforts to detect sieve effects,
and describe conditions under which observed changes to failure type distributions are
attributable to sievey-not-leaky sieve effects. We outline methods to test these conditions
and present Bayesian and frequentist methods to detect sieve effects when the conditions
hold. To our knowledge, this is the first application of Bayesian methodology to the problem
of sieve analysis.
2. Sievey-not-leaky modeling of intervention efficacy
2.1 Notation
As we introduce the SNL framework and some-or-none models, we will use the following
notational conventions. All vector-valued parameters are in bold and parameter vectors are
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named consistently so that their dimensionality and role is apparent. Lowercase subscripts
convey either the main role of the parameter, the treatment group to which it corresponds,
or an index into the (vector-valued) parameter. Table 1 describes the relevant symbols.
[Table 1 about here.]
We begin with (categorical, completely observed) outcome data Y for all n = nv + np
subjects of a (placebo-)controlled randomized trial, with Yv denoting the outcomes for just
the nv intervention recipients (that is, for those subjects for whom zi = v). Outcome types j
include the special value 0 to indicate non-failure, and the other (failure) types are labeled
such that 1 through g are failure types that are targeted by the g-or-none intervention. For
instance np0 of the np ≡
∑J
j=0 npj control recipients had not failed by the end of the trial,
and nv1 of the nv ≡
∑J
j=0 nvj treatment intervention recipients failed with failure type 1.
We let “c” (as a subscript) represent the counterfactual values of what would be seen in
the treatment group if they had not received the treatment. So for instance we define the
counterfactual total number of subjects nc as
∑J
j=0 ncj, which is equivalent to nv since by
assumption the intervention does not affect the total number of subjects (just which subjects
fail, and their corresponding failure types).
Uppercase subscripts (“G”) in the index position indicate a scalar sum over indices 1 . . . g.
For example, rcG =
∑g
j=0 pcj is the probability that a treatment-intervention recipient would
have a targeted-type failure if that subject had not received the intervention. Parameters
with initial “r” refer to outcome proportions, with “p” refer to failure proportions, and with
“q” refer to non-targeted-type proportions; so for example rpJ ≡ npJnp , vs ppJ ≡
npJ
np−np0 , vs
qpJ ≡ npJnp−(np0+npG) . Note that we also use q without a treatment group subscript to indicate
the distribution among non-targeted categories of replacement failures, as discussed below.
To be consistent with the literature on discrete marks sieve analysis, we parameterize
our approach to comparing some-or-none to all-or-none models in terms of the failure type
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frequencies pvj and ppj. Although when optimizing parameters (for maximum-likelihood
estimation) we may employ the logistic transform for more convenient search, in this article
we represent the category probabilities directly in their own simplex scale (rather than
the logistic scale). As all of the model parameters index either a binomial or multinomial
distribution family, when being Bayesian we use conjugate beta or Dirichlet priors on this
simplex scale.
2.2 No-harm, would-be-first failure processes, and replacement failures
In accord with the definition used in Gilbert et al. (1998), we define mark-specific intervention
efficacy in terms of “per-exposure” probabilities of infection (failure), given one exposure
event. Since we are not able to observe exposures, and since a single subject may experience
zero or multiple exposure events, we are not generally able to directly estimate these per-
exposure probabilities (Rhodes et al., 1996). Gilbert et al. (1998) showed that under certain
(leaky) conditions, relative risks and odds ratios of these probabilities are directly estimable.
Departing somewhat from these and other articles’ definitions of “exposure”, in this article
(and in the framework here introduced) we simplify the setting to assume that “exposure”
is defined as “an exposure that would, in the absence of intervention, result in a failure”.
Thus the per-exposure probability of failure is 1 for placebo recipients (and for intervention
recipients in the counterfactual case) for any type of failure, and variations of failure rates
across types for these subjects are due solely to variations in exposure distributions across the
failure types. Note that this definition precludes the possibility that an intervention-receiving
subject would experience a new failure that would not be experienced in the counterfactual
case. This is the “no-harm” assumption.
However, since an intervention-receiving subject might avoid (due to the intervention) the
failure that would have affected him in the counterfactual case, and is thus potentially sus-
ceptible to subsequent exposures, there may be “replacement failures” affecting intervention
Sieve analysis of non-leaky interventions 7
recipients that would never have been observed in the counterfactual case (since a subject’s
observed failure is defined as her first exposure that is not avoided).
When there are J failure types, this exposure model is equivalent to a J competing risks
model in which only the time of the “winning” exposure process is observed, where “winning”
additionally requires that the exposure is not avoided due to the intervention. Concretely, we
represent the J competing risks for each subject i with J simultaneous (and possibly jointly-
distributed) continuous-time Markov counting processes Nij(t), j ∈ 1, . . . , J , where at time
t the state of process Nij(t) is a natural number indicating the number of potential failure
events of type j that subject i would experience by time t if all such potential failures up to
time t were avoided (that is, they did not become actual failures) due to the intervention.
This is subtle, but it is important to note that Nij(t) is not the same as the counting
process of subject i’s actual failures, N ′ij(t), in which the probability of a subsequent actual
failure, given all previous failures, reflects a potential change in the subject’s susceptibility
due to the previous failures. Instead, process Nij(t) always reflects the surviving subject’s
chance of experiencing an exposure, and the state of this process represents the number of
previous would-be-failures that were avoided due to the intervention effect.
This formulation assumes independence between the failure processes of every pair of
subjects. Note, though, that we assume nothing particular about the failure processes Nij(·)
for any one subject i: they may be arbitrarily jointly distributed across the J types. In
particular we do not assume that they are memoryless or of any exponential family.
By construction, a subject who does not receive the intervention will never experience an
intervention-induced failure avoidance. We nevertheless define these “would-be-first failure
processes” for all subjects; any control-recipient subject for whom any of the J processes
Nij(τ) is non-zero at the end of the trial will have Yi > 0 (since any subject i with zi = p will
experience a failure of type j by time τ whenever Nij(τ) > 0). Since the failure type is defined
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as the mark of the first failure that actually occurs during the trial, we can define control-
recipient failure types in terms of the would-be-first failure processes as Yi = argmin
j
tij,
where tij ≡ argmin
t
Nij(t)I (Nij(t) > 0), or Yi = 0 if all J times tij are greater than τ .
2.3 Response types R
There may be a subgroup of treatment intervention recipients for whom the treatment did
not have any relevant effect. In general we allow for a subject-specific latent (unmeasured)
response variable ri ∈ R to represent subject i’s response to the intervention (eg. immune
response to vaccination), with the constraint that a unique value in the set R represents
“no response” (ri = 0), and that all control recipients (subjects for whom zi = p) have
ri = 0. We let pt represent the rate of non-zero responses among intervention recipients
(understood as an expected value over possibly varying subject-specific response rates pti, so
pt ≡ Ei[Pr(ri 6= 0|zi = v)]).
For simplicity of presentation we here consider only binary responses, R ≡ {0, 1}, where
subjects for whom ri = 1 are the subjects with “take”, whose failures are potentially influ-
enced by the intervention. We henceforth use the terms “responders” and those with “take”
interchangeably. In a setting such as genome-scan sieve analysis, in which multiple features
(genomic loci) are evaluated, the definition of “take” might be feature-specific, as in, “the
subject experienced vaccine-induced immune responses that target this locus.” We do not
represent “take” on a per-failure-type basis. In the Discussion section (below) we address the
extension of this “dichotomous-take” framework to a setting with multiple response types,
which includes the special case of models with independent per-failure-type response rates.
2.4 Failure avoidance rate vectors {ωr : r ∈ R}, some-or-none interventions
For any particular response type r ∈ R let there be a vector ωr of J values, with the
value at index j (denoted ωrj) representing the per-event (aka “per-exposure”) probability
that a subject with treatment response r avoids an event that would, in the absence of
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the intervention, have caused a failure of type j. We assume that these avoidance rates are
constant in time, leaving to future work the interesting extension to time-varying efficacy.
The setting of multiple failure types leads to an interesting variation on the “all-or-none”
versus “leaky” treatment intervention dichotomy. By definition, treatment interventions ex-
hibiting sieve effects can never be“all-or-none”(which would have equal and perfect avoidance
for all takers regardless of failure type); but they could be “some-or-none” (or “one-or-none”)
if for all r and j, ωrj ∈ {0, 1} but there exists some pair of types (j, j′) for which ωrj 6= ωrj′ .
Such an intervention induces (in takers) perfect avoidance of some but not all failure types (at
any particular time). Consider, for concreteness, a dichotomous-take one-or-none intervention
with ω1 = (1, 0, . . . , 0). We do not consider this a “leaky” intervention, since all of the IE is
determined through the take indicator ri, with no per-event stochastic filtering.
When it is not known a priori which type(s) might be the targets of the intervention, the
one-or-none and some-or-none models can be used in concert to compare different hypotheses
regarding the nature of a particular sieve effect. When the SNL sieve conditions hold (see
below), and particularly under the condition that the intervention is non-leaky, these models
reflect all possible sieve effects for which avoidance rates that are non-zero are the same for
all types at any given time. In a Bayesian setting, for instance, we can compute the posterior
probability of every possible some-or-none SNL model and compare these to the posterior
probability of the all-or-none null model.
We can also compare particular pairs of models using their posterior probabilities, or by
using likelihood ratio tests or Bayes factors. For instance we can compare the all-or-none
sieve null model (in which treatment recipient relative failure type rates are the same as
the counterfactual distribution, which we estimate from the control-recipient data) to the
particular one-or-none model in which takers avoid all type-1 failures. In the absence of
replacement failures, the only effect of the one-or-none intervention is to reduce the type-1
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failure rate for “takers” by pt, so this test compares a model reducing just type-1 rates by pt
to a model reducing all rates by pt.
2.5 The cause replacement rate p2
We can make the notion of replacement failures precise in the specific context of some-or-none
interventions with target types 1, . . . , g (ω1j = I(1 6 j 6 g)). In this context, replacement
causes imply that (nv0 + nvG) < (nc0 + ncG). Put another way, replacement failures cause
some treated subjects to fail with a non-targeted failure type who would (in the absence of
treatment) have failed with a targeted failure type, so
∑J
j=(g+1) nvj >
∑J
j=(g+1) ncj.
If we assume that a dichotomous-take some-or-none intervention is completely effective
(for subjects with relevant responses) at preventing failures of types 1 through g, then the
expected number of treatment recipients who fail with each of these types is E[nvj] = ncj(1−
pt). Let p2 be the probability that a subject who would have failed by a targeted failure type
has a replacement failure during the trial. Then the expected total number of uninfected
treatment recipients is E[nv0] = nc0+ncGpt(1−p2). The remaining subjects with intervention-
induced avoidance of their targeted failures go on to fail anyway by one of the remaining
types. Let qj be the conditional probability that the replacement failure is of type j ∈
(g+1), . . . , J , with
∑
j qj ≡ 1, so that the product p2qj is the probability that the replacement
failure occurs before the end of the trial and is of type j. Then the expected total number
of failures of type j > g among treatment recipients will be E[nvj] = ncj + nvGptp2qj.
The cause replacement rate p2 is the proportion of the ncG subjects (who in the absence
of the treatment intervention would have had targeted-type failures during the trial before
any non-targeted-type failures) with a relevant treatment response (ri = 1) for whom at
least one of the non-targeted failure processes also fails during the trial. In our notation,
p2 = Pr(∃j > g : tij′ < tij 6 τ |ri = 1,minj6g (tij′) 6 τ), where tij ≡ mint (Nij(t) = 1).
Note that the conditional distribution among the other categories (those not targeted) will
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be unaffected by a one-or-none or some-or-none intervention unless there are replacement
failures. That is, if p2 = 0, then qvj = qcj for all j > g. If instead there are replacement
failures, the conditional probabilities of the off-target failure types will increase to some
degree, since pvj =
pcj+pcGptp2qj
1−IE .
2.6 SNL sieve conditions
As we have discussed, we assume conditions of no harm and no stochastic leaks. Together,
these conditions ensure that replacement failures occur only in the presence of sieve effects,
never under the all-or-none null. In this context we still cannot guarantee that naive estimates
of mark-specific efficacy using relative rates of failure will be unbiased, since replacement
failures in the presence of sieve effects may arbitrarily and unpredictably alter the pv for
the untargeted types. However since there are a limited number of some-or-none models, if
the conditions hold then the problem of identifying a sieve effect becomes the problem of
identifying which of those models holds best.
Two additional conditions are required. First, we assume time-constancy (over the du-
ration of the trial) in all of the parameters, notably the overall IE, the two intervention
response parameters pt and ω1, the counterfactual failure type distribution pc, and the cause
replacement rate p2 and distribution q. As Gilbert (2001) discussed for the leaky-intervention
sieve analysis framework, it may be possible in future efforts to relax some of these time-
constancy constraints either by reinterpreting the model parameters (as averages over time)
or by augmenting the model.
Second, as well as requiring between-subjects independence of all outcomes, we require
independence between a subject’s response ri to the intervention and the relative failure
rates of his would-be-first failure process distributions. This is (all that is) required to avoid
the bias engendered if subjects with “take” tend to also be subjects with a particular type of
failure.
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2.7 The sieve effect strength ps
In our mathematical models of some-or-none interventions, we do not explicitly represent
the take rate pt or the cause replacement rate p2. We now introduce the primary parameter
of these models, ps ≡ pt(1−pcG(1−p2))1−ptpcG(1−p2) , which subsumes the role of those other two parameters.
As detailed in Web Appendix A, the “sieve effect strength” ps expresses the magnitude of
a sieve effect as the proportion of those subjects who would not be protected by the some-
or-none intervention who would instead be protected if the intervention were an all-or-none
intervention. That is, it reflects the extent to which an intervention’s partial efficacy can be
attributed to its sieve effect as opposed to its incomplete rate of take: the partial efficacy of
a some-or-none intervention with ps = 0 has nothing to do with sieving, whereas the partial
efficacy of a some-or-none intervention with ps = 1 is completely attributable to its sieve
effect.
Note that the SNL framework implies the constraint IE 6 ptpcG. As elucidated in Web
Appendix B, this constraint can be expressed solely in terms of the some-or-none model
parameters IE, pcG, amd ps. See Web Appendix C for a mathematical representation of the
some-or-none model likelihood in the SNL framework.
2.8 Replacement-only models and ps
If IE = 0 (“replacement-only”), the sieve effect strength parameter ps becomes equivalent
to the take rate pt, and all avoided failures of the targeted types are replaced (that is,
p2 = 1). Then the conditional probabilities of the off-target failure types (j > g) will be
pvj = pcj + pcGpsqj, and for the targeted types j ∈ 1, . . . , g, pvj = pcj(1− ps).
The replacement-only all-or-none model and the replacement-only some-or-none model
constrained to ps = 0 have the same conditional likelihood of the failure categories pvj
as the counterfactual pcj. Thus the likelihood is mathematically equivalent between them,
which makes the likelihood ratio test comparing the all-or-none to the some-or-none model
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a candidate for Wilks’s theorem (of an asymptotic chi-squared distribution with one degree
of freedom, reflecting model equivalence when the parameter ps is zero), but only when
IE = 0. In the Results section, we demonstrate in simulations that the chi-squared(1) null
distribution holds well for replacement-only scenarios. We also show that a chi-squared(1)
null controls size in our numerical experiments even for cases with IE > 0.
2.9 MBS, replacement-only, and insert-only models
We previously introduced an approach, “Model-Based Sieve” (MBS) (Rolland and Edlefsen
et al., 2012), that is closely related to replacement-only one-or-none models in the SNL
framework. Briefly, the MBS method compares the probability of the intervention-recipient
failures given a “null” multinomial model with parameters estimated as being proportional
to the observed placebo-recipient frequencies (plus pseudocounts of 1/J per category) to
the “alternative” model probability that is computed as the expected value (over an “insert-
only” indicator parameter, i ∼ Bernoulli(0.5), and a “sieve effect strength” parameter, ps ∼
Uniform(0, 1)) of the probability of the intervention-recipient sequences given a multinomial
model in which the probability of the targeted type is multiplied by (1−ps) and the removed
mass is reallocated either proportionally (if i is 1) or uniformly (if i is 0) among the remaining
categories.
The MBS approach employs a special case of the replacement-only one-or-none model. As
such it is relevant for the evaluation of post-acquisition effects, in which failure types may be
redistributed due to the intervention, but any subject who would have failed in the absence
of the intervention also fails in the presence of it. The MBS method compares (using Bayes
factor) the all-or-none null model to an even mixture of two one-or-none models (both of
which assume no intervention efficacy). Unlike the other some-or-none SNL models, MBS
does not average over a prior distribution for the replacement distribution q (nor does it
compute an MLE). The two components of the mixture model differ in their choice of q: one
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model uses an evenly-distributed q replacement vector and the other (called the “insert-only”
model) uses qj ≡ pcj1−pcG = qcj.
The mixture model employed by the MBS approach effectively combines two models
that vary in whether the effect is restricted to the targeted types or also affects off-target
types. In general when IE = 0 (“replacement-only”), qvj =
pcj+pcGpsqj
1−pvG =
pcj+pcGpsqj
1−pcG(1−ps) =
(qcj +
pcGps
1−pcG qj)
1−pcG
1−pcG(1−ps) . Thus under the additional condition of the insert-only model (that
qj = qcj), qvj = (qcj(1 +
pcGps
1−pcG ))
1−pcG
1−pcG(1−ps) , and since (1 +
pcGps
1−pcG ) =
1−pcG
1−pcG(1−ps) , qvj = qcj.
Therefore the effect of a some-or-none treatment under the insert-only model is entirely
restricted to reducing relative failure rates against the targeted types (there is no effect
on the conditional distributions of the remaining types), a fact that motivated the name
of this model (“insert-only”). The name reflects the common situation in efficacy trials
where a vaccine only protects against pathogen serotypes included in the vaccine immunogen
(“insert”).
2.10 Two-phase modeling
Bayes factors for the MBS method are calculated using only the intervention-recipient data,
after first using the placebo-recipient data to update priors on the counterfactual failure type
distribution pc. We call this approach “two-phase” because the placebo-recipient data is used
in a first phase of analysis (to update priors) and then only vaccine-recipient data is used in
a second phase.
Although in a Bayesian setting it is natural to model the parameters hierarchically to incor-
porate prior uncertainty about them, non-hierarchical approaches are also reasonable when
parameter uncertainty is small or as an approximation to a fully hierarchical approach. The
MBS method is a “hierarchical two-phase” method, in that the Bayes factors are computed
for the conditional distribution of the intervention-recipient failure count data alone, after
first using the placebo-recipient data to update the prior distribution of pc.
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3. Results
We created reference implementations (in R) for hypothesis tests based on log-likelihood
ratios and Bayes factors (for comparing all-or-none to individual some-or-none models).
Using these implementations, we use a simulation study to show that p-values approximated
using chi-squared distributions (with one degree of freedom) control size in the context of
a small-sample example setting, even for non-replacement-only scenarios. We show that the
simple decision rule to reject the null hypothesis (of no sieve effect) whenever the Bayes factor
favors the alternative hypothesis (of a particular some-or-none sieve effect) yields a powerful
hypothesis testing procedure in the frequentist sense (and in our simulations controls size
fairly well), though as expected the benefits of the Bayesian approach are most relevant to
inference (such as investigating the posterior distribution of ps) than to frequentist hypothesis
testing; we also provide a comparison of Bayesian approaches using the area under receiver
operating characteristic (ROC) curves (which consider all possible prior model odds). We
show that a Bayesian-frequentist hybrid approach of determining a null distribution for the
Bayes factor through permutation of class labels retains much of the power of the direct
Bayes factor approach (while guaranteeing size control under the permuted null). We also
demonstrate the power of these methods in comparison existing methods. Finally, we perform
a new sieve analysis of two sites found previously to exhibit sieve effects in actual HIV-
1 vaccine trial infection data. Our analyses support the sieve effects at these sights and
provide new analyses of the “sieve effect strengths” of these effects.
3.1 The simulation study
For the simulation study we considered J = 5 failure types and g = 1 targeted type. We
simulated outcome counts for models with a 10% failure rate among np = 1000 placebo
recipients (rc0 = .9). Mimicking the typically-geometric distribution across amino acids
observed at a typical locus in our HIV-1 genome-scanning applications, we set the simulated
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data pc vector given by pc ≡ (0.815, 0.171, 0.0135, 0.0005, 0.000006). When simulating from
an insert-only model, we set the replacement distribution q proportional to the non-targeted
type elements of pc, and for non-insert-only models we set q to be uniform (q ∝ 1). We also
simulated nv = 1000 intervention-recipient outcomes from the one-or-none (or all-or-none)
model.
We generated 1000 simulated data sets for each of eleven scenarios. The constraints of
the model prohibit simulation of the case with IE = 0.5, ps = 0.15 so we use IE = 0.2
for that scenario instead. Otherwise, these cases cover all non-insert-only scenarios with
IE ∈ {0, 0.50} and ps ∈ {0.15, 0.25, 0.50}, as well as the replacement-only insert-only cases
(in which q ∝ pc). We omit the other insert-only scenarios, which as discussed in Web
Appendix D differ only in their value of IE from these replacement-only insert-only scenarios.
To evaluate the size of the tests, we include two null distributions: the all-or-none null
with IE = 0.5 exhibits no sieve effects because the data are simulated without such effects;
the permuted one-or-none null is created by simulating 1000 datasets from the one-or-none
scenario, then independently permuting treatment labels of each one.
Note that while the total sample size in all of these scenarios is fixed at nv = np = 1000,
the effective sample size for estimating all parameters other than IE depends on the value of
IE. Thus for the simulations in which IE = 0, about 100 vaccine recipients become infected,
whereas for IE = 0.20, about 80 do, and for IE = 0.50, about 50 vaccine recipients become
infected in each of the 1000 randomly generated datasets per scenario. This cautions against
comparisons of power across scenarios with different values of IE.
These simulated datasets were used to evaluate several variations of the sievy-not-leaky
methods, as well as the “GWJ” nonparametric (permutation-based) t-test (statistic ZA2
in Gilbert et al., 2008), and a simple Fisher’s exact test of the failure tables (including
only counts of failures). Of the many possible SNL approaches, here we evaluate two fully
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frequentist approaches that compare minus two times the log-likelihood ratio (LLR) to a chi-
squared with one degree of freedom (“1phase” and “2phase”), rejecting the null hypothesis
when the test statistic exceeds the 95th percentile of the analytic null distribution. We also
evaluate three Bayesian procedures (“BF1ph”, “BF2ph”, “MBS-BF”) based on comparing
the estimated Bayes factors (BFs) to 1 (“rejecting” whenever BF > 1), and permuted-null
versions of each (“BF1ph-perm”, “BF2ph-perm”, and “MBS”, respectively).
As depicted in Figure 4, we found that using analytic likelihood ratio tests to compare the
one-or-none model to the all-or-none null model controls size effectively (even in IE > 0 cases
in which Wilks’s theorem does not apply), is powerful for detecting weak sieve effects, and is
robust to variations in the assumptions governing the generating model (non-replacement-
only, replacement-only, and replacement-only insert-only). The replacement-only scenarios
are indicated by “I.E=0”.
[Figure 1 about here.]
We also found that for maximum-likelihood methods the two-phase approach performed
comparably to the one-phase approach, and for the Bayesian methods it performed much
better (a point we will address further below).
Indeed the only method with competitive power to the one-phase analytic-null approach
in these simulations is the “MBS-BF” method, which in these examples also controls size
reasonably well, but in general is not guaranteed to do so. Note that in these simulations, MBS
(and MBS-BF) perform well for scenarios with IE > 0, despite employing only replacement-
only models.
In these simulation experiments we also found that a simple test based on Bayes factors
(rejecting the null hypothesis whenever the BF favors the one-or-none model over the all-or-
none null model) performed consistently well, both with the one-phase and two-phase models
(“BF1ph” and “BF2ph”) and with the MBS replacement-only mixture model (“MBS-BF”).
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However, this procedure is not guaranteed to control size at a nominal rate. A more apt
evaluation of the Bayesian methods, which assesses the area under the ROC curves, shows
that over the range of thresholds on the Bayes factors, the some-or-none two-phase approach
outperforms the MBS-BF approach for non-replacement-only scenarios, as shown in Figure 4.
Variations of these methods (“BF1ph-perm”, “BF2ph-perm”, and “MBS”, respectively), that
compare the data-estimated Bayes factors to null distributions estimated by permutation
of the class labels, are guaranteed to control size (for that fixed-margin null), with some
sacrifice of power.
[Figure 2 about here.]
For this example data, the Fisher’s exact test performed well for detecting moderate-
sized sieve effects. The Gilbert, Wu, Jobes non-parametric t-test, evaluated using the HIV-b
substitution matrix, performed relatively poorly in comparison to the other methods, partic-
ularly for the scenarios in which the non-insert distribution matters (all but the “insert-only”
scenarios). GWJ performs particularly well for the insert-only scenarios because the HIV-
b weight matrix strongly differentiates the target category from the untargeted categories,
but doesn’t differentiate much among the untargeted categories (so the GWJ test with this
matrix approximates a dichotomized Fisher test, little influenced by the distribution of the
untargeted categories).
The new approaches outshine GWJ and Fisher for low ps values (see ps = 0.15 results for
IE = 0 and IE = 0.2) when the non-insert distribution matters. In practice, the new methods
can be seen as a complement to the routinely-used GWJ method, and can aptly be described
as being more sensitive than GWJ to differences among non-targeted categories.
3.2 STEP
The sieve analysis of the breakthrough infections in the STEP (HVTN 502) HIV-1 vaccine
trial identified a strong sieve effect at site Gag 84 (Rolland et al., 2011). Because the
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STEP vaccine was designed to elicit T cell responses that target HIV-1 after infection, it is
reasonable in this case to consider a replacement-only model. Since the estimated vaccine
efficacy was negative, this analysis should be viewed with caution as the SNL “no-harm”
condition may not hold. The upcoming sieve analysis of the HVTN 505 HIV-1 vaccine efficacy
trial, which was recently halted to new enrollments due to a finding of efficacy futility, will be
a better example of a zero-efficacy setting. We present this analysis of HVTN 502 infections
as a demonstration of how the SNL methods could be applied to HVTN 505 or similar
settings.
Table 2 depicts the failure types observed at site Gag 84 among STEP participants who
experienced HIV-1 infections during the trial. The sieve effect is so strong that power
differences among testing procedures are not relevant. We can easily detect this effect, for
instance, with a Fisher’s exact test (p = 0.001).
[Table 2 about here.]
Investigating these data with a two-phase analysis comparing the one-or-none model to
the all-or-none model, we compute the log-likelihood ratio as -16.5, which has an (analytic)
p-value of 9.3e-09, strongly supporting the one-or-none model over the all-or-none model at
this site. To take a more conservative approach, we permute the treatment labels as described
above, to estimate a null distribution that conditions on the marginal totals. Since none of
these 1000 permuted-data -2*LLRs was as large as the observed value of 32.99, we estimate
the p-value as p < 0.001, again supporting a sieve effect.
[Figure 3 about here.]
Now we turn to a Bayesian approach. Figure 4 shows the approximate posterior distribution
of ps at this site when employing a hierarchical two-phase Bayesian approach (in which we use
the placebo-recipient data to update priors on both q and pc). The posterior-maximizing
value of ps is 0.68, which we could interpret as indicating that about two-thirds of the
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intervention recipients who became HIV-1 infected experienced immune escape at this locus
that they would not have experienced in the absence of the intervention. Since this analysis
depends on the no-harm assumption, this interpretation should be made cautiously.
3.3 RV144
The sieve analysis of the breakthrough infections in the RV144 HIV-1 vaccine trial identified
a moderate sieve effect at site Env 169 (Rolland and Edlefsen et al., 2012). The trial had an
estimated intervention efficacy of 31% overall, so unlike the STEP analysis, here we need not
assume a replacement-only model. Table 2 depicts the failure types observed at site Env 169
among the 109 RV144 participants who experienced infections during the trial by subtype
AE (CRF-01) HIV-1 viruses. The effect is weaker at this site, so power differences between
testing procedures are relevant. We would not detect this effect, for instance, with a Fisher’s
exact test (p = 0.089).
We now investigate this site using the dichotomous-take SNL framework, with a two-phase
analysis comparing the one-or-none model to the all-or-none model. We compute the two-
phase log-likelihood ratio as -31.95, which has an (asymptotic) p-value of 1.3e-15, indicating
strong evidence supporting a sieve effect. Since IE > 0, we do not expect Wilks’s theorem to
apply under the null. To take a more conservative approach, we permute the treatment labels
to estimate a null distribution. Three of the 1000 permuted-data −2⊗LLRs were larger than
the observed value of 63.9, so this result is much less significant than when employing the
chi-squared null.
Now we turn to a Bayesian approach. We estimate the hierarchical (for both pc and q)
two-phase Bayes factor at this site to be 3.1e+10, which is much greater than 1 and thus
supports the one-or-none model over the all-or-none model. In Figure 4 we investigate the
posterior distribution of ps at RV144 site Env 169.
[Figure 4 about here.]
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The posterior-maximizing value of ps is 0.24, which we interpret as indicating that about
one-quarter of the intervention recipients who became HIV-1 infected would not have become
infected if the intervention had targeted all amino acids at site Env 169 rather than just the
insert AA. That is, the HIV-1 infecting these subjects was able to escape the vaccine-induced
immune pressure because the intervention targeted just the K, not the other AAs, at site
Env 169. This analysis suggests that the incompleteness of the efficacy can only partly be
attributed to the sieve effect. In this non-replacement-only case, the sieve effect strength is not
simply equivalent to the rate of “take”; as discussed in section 2.7, the interpretation is that
incomplete“take”accounts for 1−ps (about three-quarters) of the unavoided vaccine-recipient
failures, indicating that even if the vaccine had induced (in takers) immune responses that
successfully targeted all amino acids at Env 169, the vaccine would still have been only
partially efficacious (efficacy would have been about 50% rather than 31%).
4. Discussion
We have introduced a framework for sieve analysis of non-leaky interventions that do not
cause harm (the intervention induces only “failure avoidance”, not new failures except as
replacements of avoided failures). The framework provides a useful platform for reasoning
about sieve effects, and we argue that apparent sieve effects are not generally attributable
to actual differential efficacy across failure types except under either the “leaky” conditions
of Gilbert et al. (1998), or under the no-harm, non-leaky conditions of this framework.
We have introduced models for evaluating sieve effects in this sievey-not-leaky setting.
We have implemented both frequentist and Bayesian procedures, and we have demonstrated
the power of both frequentist and Bayesian-frequentist hybrid approaches under various
conditions. The primary parameter of the model, the “sieve effect strength” ps, has the useful
interpretation that it reflects the amount of an intervention’s partial efficacy that can be
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attributed to the sieve effect (as opposed to incomplete “take” of the intervention by some
intervention recipients).
For replacement-only (IE = 0) scenarios, since the all-or-none model is nested in any some-
or-none model whenever ps = 0, the hypothesis test based on likelihood ratios has a simple
asymptotic analytic form. We found in our simulation experiments that the same analytic
approach works well for scenarios with IE > 0 (to which the asymptotics do not apply).
The SNL framework that we have introduced is generalizable beyond the dichotomous
“take” assumptions that we have employed here. At the extreme, we could allow non-zero
probabilities for all of the 2J possible response types allowed by the some-or-none framework
(these index the set of types that are targeted, including both “all” and “none”). One
particular example would constrain these to ensure independent “take” probabilities for each
targeted type. It remains for future work to develop models and tests for this scenario.
With now two sieve analysis frameworks for two extremes of the spectrum (leaky inter-
ventions with 100% “take” and this new approach for non-leaky interventions with partial
“take”), there remains a need for development of methods that support unbiased evaluation of
sieve effects under conditions of both leaky and incomplete-take interventions. In the mean
time, or if that is not possible, there remains a need for further development of tests to
evaluate the conditions under which these methods yield reliable results.
We conclude with a brief discussion of the “no-harm” assumption. Mathematically, the no-
harm condition requires that the per-exposure probabilities of infection are always 1 under
the control (or counterfactual or no-take) intervention scenario. This means that “exposure”
is equated with “an exposure that would result in infection in the absence of the treatment
intervention.” Here, the definition of “exposure” reflects a modeling choice that determines
the tradeoff between the per-exposure probabilities and the exposure distributions.
For partially effective interventions, the choice may be arbitrary, but it is clearly not a
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reasonable assumption for an intervention with a significantly negative estimated efficacy. In
such scenarios, it may still be possible to use the sievey-not-leaky failure avoidance framework
by considering the control intervention an alternative treatment, and supposing a shared set
of would-be-first failures (in a no-harm setting) that are avoided at different rates by the two
interventions. We leave this to future work.
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Appendix
Web Appendix A: The sieve effect strength ps
Here we show that the“sieve effect strength”ps expresses the magnitude of a sieve effect as the
proportion of those subjects who would not be protected by the some-or-none intervention
who would instead be protected if the intervention were an all-or-none intervention.
Note that an all-or-none intervention has the property that for all failure types j ∈ 1, . . . , J ,
pvj = pcj. If the intervention is effective (ie if pt > 0) then all responders who would have
failed are instead protected, so rv0 = rc0 + (1− rc0)pt, and the intervention reduces the rates
of all failures by the same amount, pt.
In contrast, only a subset of the responders would be protected by a some-or-none inter-
vention: only the subjects who would have failed with a targeted-type failure in the absence
of any intervention. Also, in order to be protected a subject must have no (untargeted)
replacement failures. Thus for a one-or-none intervention, rv0 = rc0 + rc1pt(1 − p2). For
a some-or-none intervention, with ω1j = 1 for categories j ∈ 1, . . . , g and zero otherwise,
rv0 = rc0 + rcGpt(1− p2).
For some-or-none models with g > 1, both pvG = pcG(1−ps) (overall) and pvj = pcj(1−ps)
(for each j ∈ 1, . . . , g). This derives from pvG = pcG(1 − ps), since pvj = pvG pcjpcG so pvj =
pcjpcG(1−ps)
pcG
= pcj(1 − ps). This also means that simultaneously, ps = 1 − pvGpcG (overall) and
ps = 1 − pvjpcj (for each j ∈ 1, . . . , g), and therefore that the relative rate of type-specific
intervention-associated reduction in failures is constant across the targeted categories. This
is consistent with the SNL sieve condition that ensures that a subject’s probability of having
response ri = 1 is independent of the rates of her would-be-first failure processes.
The failure type target(s) of a one-or-none or some-or-none intervention will be affected
differently than the off-target categories. For some-or-none interventions targeting types 1
through g, rvj = rcj(1− pt) for all j ∈ 1, . . . , g and ps ≡ pt(1−pcG(1−p2))1−ptpcG(1−p2) .
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To see that the sieve effect strength reflects the amount of an intervention’s partial efficacy
that can be attributed to the sieve effect, consider first that its denominator is 1− IE, where
IE is the intervention’s efficacy as defined by the fraction of the subjects that would have
failed in the absence of the intervention who did not fail in the presence of it:
IE = 1− nv − nv0
nc − nc0 =
ncGpt(1− p2)
nc − nc0 = pcGpt(1− p2).
Another interpretation of the denominator 1 − ptpcG(1 − p2) of the sieve effect strength
ps is that it is the probability, for a person who would have failed in the absence of any
intervention, of that person still failing despite being given the some-or-none intervention.
The additive inverse of the sieve effect strength parameter is (1− ps) = 1−pt1−ptpcG(1−p2) , which
is the probability that a subject is not a responder (1− pt) divided by the probability that
a failure would not be avoided in the setting of a some-or-none intervention. The all-or-none
intervention protects all responders, so (1−ps) is the ratio of failures not avoided by the two
intervention types (all-or-none vs. some-or-none), and the sieve effect strength is the fraction
of those not protected by the some-or-none intervention whose non-protection is attributable
to the some-type versus all-type coverage (that is, attributable to the sieve effect). The rest
of the non-protection is attributable to incomplete take (ie. the fact that pt < 1) and would
be experienced with both types of intervention.
Web Appendix B: General constraints implied by the some-or-none model
In general, IE 6 ptpcG for all some-or-none models, with or without replacement failures,
and thus (since pt 6 1), IE 6 pcG. Circumstances in which IE > pcG are unlikely to be well-
modeled by dichotomous-take non-leaky some-or-none failure avoidance models targeting
types 1, . . . , g. This could in principle lead to a pre-screening procedure to exclude from
consideration any some-or-none model in significant violation of the condition that IE 6 pcG.
We leave details to future work.
Each of the parameters of the some-or-none model is directly estimable from the data,
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given the other parameters. By plugging-in estimates IˆE, pˆvj, and pˆpj of IE, pvj and pcj
for j ∈ 1, . . . , J , the sieve effect strength can be estimated by pˆs = 1 − ˆpvGˆppG , the marginal
response rate by pˆt = 1− 1−pˆs1−IˆE , and the cause replacement rate by pˆ2 = 1−
IˆE
ˆpcGpˆt
. Even the
conditional category replacement distribution can be estimated, since for non-targeted types,
qˆj =
(1−IˆE) ˆpvj− ˆpcj
ˆpcGpˆtpˆ2
. These plug-in estimates will not always satisfy all of the simultaneous
constraints, however, such as the constraint that
∑
qˆj = 1 or the constraints that individual
parameters are valid probabilities (eg pˆ2 must satisfy 0 6 pˆ2 6 1).
All required constraints will be satisfied under the bounds imposed by our parameterization
if (and only if) the following relation holds: IE 6 pcGpt. This constraint can be equivalently
expressed as a one-sided boundary on any one value in the set {IE, pcG, ps}, given the other
two values:
IE 6
pcGps
1− pcG(1− ps) ; and
pcG >
IE
ps + IE(1− ps) ; and
ps >
IE(1− pcG)
pcG(1− IE) ,
(A.1)
but often in practice we enforce the constraint via the alternate equivalent expression, IE 6
pcG(1− ((1− ps)(1− IE))).
Note that this constraint implies that IE 6 pcG, since pt 6 1.
In some settings additional constraints arise, such as when p2 is assumed equal to zero
(under the assumption of no replacement failures), which implies the additional constraint
that pvG =
pcG−IE
1−IE , or when p2 is assumed equal to one (under the replacement-only model),
which implies the additional constraint that IE = 0. We sometimes specify (rather than
estimate) the conditional replacement type distribution qj for j > g, which also constrains
the other parameter estimates.
There will not generally be a some-or-none model that fits the naive plug-in estimates (such
that all the constraints are satisfied). The some-or-none model with maximum likelihood will
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employ parameter estimates that deviate from the naive MLEs. One strategy, discussed in
the main text (the two-phase non-hierarchical approach), is to perform the some-or-none
model fit under conditions of fixed estimates of IE, rc0 and the vector of pcj values. In these
circumstances the model’s constraints restrict the estimates of the values of pvj through
parameters ps and qj.
When ps = 0, all replacement-only some-or-none models become equivalent to the replacement-
only all-or-none model (with IE = 0).
In the replacement-only some-or-none model, setting ps = 0 forces pt = IE = 0 (since
ps = 1− 1−pt1−IE ). The all-or-none model also has pt = IE, since (in that model)
IE = 1− (1− rv0)/(1− rc0)
= 1− (1− (rc0 + rcGpt))/(1− rc0)
=
(1− rc0)− (1− (rc0 + rcGpt))
1− rc0
=
rcGpt
1− rc0 = ptpcG,
(A.2)
and pcG = 1.
Web Appendix C: Some-or-none model likelihood
We express the likelihood in terms of the primary parameters, pc = {pcj : j ∈ 1, . . . , J}, ps,
IE, rc0, and q = {qj : j ∈ (g+ 1), . . . , J}. rc0 is included because IE = 1− 1−rv01−rc0 , and the full
likelihood involves
Pr(np0, nv0|rc0, rv0, np, nv) = Pb(np0|np, rc0)Pb(nv0|nv, rv0),
where Pb(x|n, p) represents the probability of X = x when X is a random variable following
a binomial law with parameters n and p. The rest of the likelihood does not depend on rv0
and rc0 except through IE. Therefore, when IE is known (or assumed equal to 0 as in the
“replacement-only” models), this contribution from the non-failing subject count data to the
overall likelihood cancels in the context of a likelihood ratio statistic or a Bayes factor.
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Here we present the full joint likelihood for a some-or-none model under the conditions of
the dichotomous-take non-leaky failure avoidance “SNL” framework, which (for a some-or-
none intervention targeting types 1, . . . , g) is given by
Pr(Y |M g−or−nonea ,pc, ps, IE, rc0, q) =
Pr(np0, nv0|IE, rc0, np, nv)
× Pm(np|pc)Pm(nv = {nvj : j ∈ 1, . . . , J}|pv = {pvj : j ∈ 1, . . . , J}),
(A.3)
where
pvj = pcj(1− ps)I(j ∈ 1, . . . , g)
+
pcj + pcGptp2qj
1− IE I(j ∈ (g + 1), . . . , J),
(A.4)
and where Pm(x|p) represents the probability of counts x under a multinomial model with
parameters n =
∑
xj and p.
Note that since p2 = 1− IEpcGpt =
pcGpt−IE
pcGpt
, pcGp2pt = pcGpt − IE. Also, since 1− ps = 1−pt1−IE ,
pt = 1 − (1 − ps)(1 − IE). Thus pcGp2pt = pcG(1 − (1 − ps)(1 − IE)) − IE. Then pvj in the
likelihood can be expressed solely in terms of the primary parameters as
pvj = pcj(1− ps)I(j ∈ 1, . . . , g)
+
pcj + (pcG(1− (1− ps)(1− IE))− IE)qj
1− IE I(j ∈ (g + 1), . . . , J).
(A.5)
Web Appendix D: Equivalence of the three insert-only models
There are three types of insert-only model: either p2 = 0, in which case we call it the “no
replacement insert-only model”, or q = qc, which we further differentiate by whether IE = 0,
in which case we call it the “replacement-only insert-only model”, or IE > 0, in which case
we call it the “non-replacement-only insert-only model”. Here we show that all three of these
are equivalent in their expressions of the category probabilities pv.
Note that these models are not exactly equivalent. For example, in the “no replacement
insert-only”, ps =
pt(1−pc1)
1−ptpc1 , whereas in the “replacement-only insert-only” model, ps = pt, and
for the “non-replacement-only insert-only” model, ps ≡ pt(1−pcG(1−p2))1−ptpcG(1−p2) .
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However, they all involve no intervention effect on the conditional distribution among the
non-targeted categories, since when p2 = 0, qvj = qcj for all j > g. Since also in all models,
pvj = pcj(1− ps) for targeted types j ∈ 1, . . . , g, for practical purposes when expressed using
ps, the models are equivalent. Their only difference is in interpretation of the sieve effect
strength ps in relation to pt and IE.
In the setting of the replacement-only insert-only model, IE = 0 and ps = pt, but in the
some-or-none model with no replacement failures, 1− ps = 1−pt1−IE = 1−
pt(1−pc1)
1−ptpc1 , so pt =
IE
pcG
,
ps =
IE
1−IE
1−pcG
pcG
, and pv1 = pcG(1− ps) = pcG−IE1−IE .
Thus in the “no replacement insert-only” model, the fraction of failures that are of the
targeted types is reduced by an amount proportional to the intervention effect, whereas in
the “replacement-only insert-only” model there is no intervention effect, and the fraction is
instead reduced by an amount proportional to the “take” response rate. The interpretation
of ps for the “non-replacement-only insert-only” model is the same as for the general some-
or-none model with arbitrary replacement distribution q.
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Figure 1. Simulation study rejection rates heatmap, by scenario (row) and method
(column). These methods and scenarios are described in the main text. Numbers in cells
indicate the fraction of the 1000 scenario simulated data sets for which the method’s decision
rule favored the hypothesis of a sieve effect over no sieve effect. Cells are shaded or colored,
with higher values in darker-colored cells. As all frequentist tests are conducted at size
α = 0.05, the values in the bottom two rows (the null-distributed data scenarios) are at or
near 0.05 except for the Bayesian decisions (“MBS”, “BF1ph”, and “BF2ph”.
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Figure 2. ROC Curves comparing Bayesian testing methods, for scenarios with ps = 0.15.
Figures in the left column (a, c, and e) use the permuted null scenario data as the true-
negatives, whereas figures in the right column (b, d, and f) use the all-or-none null data.
Figures in the first row (a, b) use the IE = 0.2 (non-replacement-only) scenario data as the
true-positives, whereas figures in the second (c, d) and third (e, f) rows use the insert-only
and replacement-only IE = 0 scenario data, respectively.
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Figure 3. Two-phase hierarchical one-or-none evaluation of STEP site Gag 84: The
approximate posterior distribution of ps, evaluated using 1000 Monte Carlo simulations per
point. The Y axis is log-scaled and unnormalized. The posterior mass is concentrated well
above zero, which since IE = 0 indicates evidence for a sieve effect.
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Figure 4. Two-phase hierarchical one-or-none evaluation of RV144 site Env 169: The
approximate posterior distribution of ps, evaluated using 1000 Monte Carlo simulations
per point. The Y axis is log-scaled and unnormalized. The posterior mass is concentrated
near ps = 0.24, indicating that about that fraction of the partial efficacy of RV144 can be
attributed to the sieve effect.
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Table 1
Notation symbols and their meanings
role index
category symbol meaning range subscripts subscripts
J number failure categories N+
g number targeted categories 1 . . . J
R set of response categories R = {0, 1}
τ (time) duration of the trial R+
initial z treatment group {p, v} i
initial n outcome count N p, v, c j
initial p probability [0, 1] r, s
initial r “take” response indicator R i
initial Y outcomes for each subject 0 . . . J p, v, c i
initial n count simplex [0, 1]J+1 p, v, c j
initial r probability simplex [0, 1]J+1 p, v, c j > 0
initial p probability simplex [0, 1]J p, v, c j > 0
initial q probability simplex [0, 1]J−g p, v, c j > g
initial ti exposure times for subject i (0, τ) j > 0
initial ωr failure avoidance rates for response r [0, 1] j > 0
subscript i index for subjects 1 . . . n
subscript j index for outcome types 0 . . . J
subscript p control treatment group
subscript v intervention treatment group
subscript c counterfactual for intervention group
special t pt ≡ Pr(“take” response)
special 2 p2 ≡ Pr(avoided failure is replaced)
special s ps ≡ the “sieve effect strength”
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Table 2
STEP failure types at site Gag 84 and RV144 non-failure counts (labeled “0”) and failure types at site Env 169
Gag 84 Env 169
T V 0 K Q R E T V
V 8 31 7909 30 9 2 1 1 1
P 17 9 7914 57 7 2 0 0 0
